Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Reports Interim Data From Troubled Campath Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Multiple sclerosis therapy meets efficacy endpoints, but safety issues remain.

You may also be interested in...



CDER Taps Genzyme Exec As Deputy Director For Science Operations

Richard Moscicki will fill new position that will help oversee center operations and provide “executive direction,” joining fellow deputy directors Robert Temple and Douglas Throckmorton.

Genzyme Plans Campath MS Launch In 2009

Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.

Genzyme Plans Campath MS Launch In 2009

Alemtuzumab Phase III trials in patients with multiple sclerosis are expected to begin next year.

Topics

Latest News
UsernamePublicRestriction

Register

PS064860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel